ClinicalTrials.gg
CompletedNCT02187484Updated Jul 11, 2014

BIBR 277 Capsules in Hypertensive Patients With Nephropathy

A Phase 2 interventional study of BIBR 277 in Hypertension, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-07-11.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Enrollment
94th of 99
23 · median 184
Started
1998
with 5 others
Phase 2
4 of 99
none open now
Registered
65th of 99
by date
Lead sponsor
48 of 99
Boehringer Ingelheim

Among the 99 studies testing telmisartan in Hypertension, this one is the 94th largest by enrollment, is one of 6 that started in 1998, is one of 4 in phase 2, and was the 65th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

The antihypertensive effect, safety and usefulness of treatment with BIBR 277 capsules were evaluated in hypertensive patients with nephropathy

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Condition: Either of the following criteria is satisfied in laboratory tests:

    • Presence of a renal parenchymal disorder such as chronic glomerulonephritis is confirmed (serum creatinine \< 3.0 mg/dL)
    • Presence of a renal function disorder (serum creatinine ≥ 1.5 mg/dL to \< 3.0 mg/dL)
  • Age: ≥ 20 years
  • Sex: Either male or female
  • Patient status: Either outpatients or inpatients. However, the patient status should remain unchanged throughout the study period
  • Blood pressure (BP):

    • [Outpatients] The last 2 measurements of sitting BP out of at least 3 taken during the observation period (2 - 4 weeks) should be stable and a mean of the two measurements should be ≥160 mmHg for systolic BP (SBP) and ≥95 mmHg for diastolic BP (DBP)
    • [Inpatients] The last 2 measurements of supine BP taken during the observation period (1 week) should be stable and a mean of the 2 measurements should be ≥ 150 mmHg for SBP and ≥ 90 mmHg for DBP

Exclusion criteria

Exclusion Criteria:

  • Renovascular hypertension
  • Undergoing haemodialysis
  • Severe hypertension (Diastolic BP ≥ 120 mmHg)
  • Severe heart failure, angina pectoris, or history of myocardial infarction
  • Atrioventricular conduction disturbance (degree II to III), atrial fibrillation, or serious arrhythmia
  • Symptoms of cerebrovascular disorder
  • Serious hepatic dysfunction
  • Uncontrolled diabetes
  • Peptic ulcer
  • History of to drugs
  • Hyperkalaemia
  • Undergoing treatment with a digitalis preparation
  • Pregnant, breast feeding, possibly pregnant or planning to become pregnant during this study
  • Otherwise judged ineligible by the investigator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Single rising doses of BIBR 277

    Drug: BIBR 277

Interventions

06

What researchers measure

Primary outcomes

  1. Changes from baseline in hypertensive effect by investigator, using a 5-grade classification

    Time frame: 8 weeks after start of treatment

Secondary outcomes

  1. Changes from baseline in blood pressure reduction

    Time frame: 8 weeks after start of treatment

  2. Rate of blood pressure normalisation

    percentage of patients with \< 150/90 mmHg

    Time frame: 8 weeks after start of treatment

  3. Changes from baseline in blood pressure / pulse rate

    Time frame: 8 weeks after start of treatment

  4. Usefulness assessment by investigator, using a 5- grade classification

    Time frame: 8 weeks after start of treatment

  5. Overall safety assessment by investigator, using a 5- grade classification

    Time frame: 8 weeks after start of treatment

  6. Number of patients with adverse events

    Time frame: Up to 12 weeks

  7. Number of patients with abnormal changes in laboratory values

    Time frame: Up to 8 weeks after start of treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 1998 and a primary completion of Aug 1999. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2014
First posted
Jul 11, 2014
Start
Aug 1998
Primary completionActual
Aug 1999
Last update
Jul 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02187484
Responsible party
Sponsor
First posted
Jul 11, 2014
Start date
Aug 1998
Primary completion
Aug 1999
Last update
Jul 11, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telmisartan

Start the discussion